Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRN | P28799 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22672598 | 0.86 | ALDH1A1 (0.56) | ALDH1A1HPGDALOX15HSD17B10NPC1 | |
| SCHEMBL7448063 | 0.86 | TGFBR1 (0.47) | TGFBR1ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL22214078 | 0.78 | SCN9A (0.41) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22955472 | 0.76 | TGFBR1 (0.49) | TGFBR1ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL19966737 | 0.76 | HPGDS (0.50) | NPC1RAB9ASMN1; SMN2SCN4AEGLN1 | |
| SCHEMBL22797574 | 0.74 | LCK (0.48) | NPC1RAB9ASMN1; SMN2SCN4AMAPT | |
| SCHEMBL10199295 | 0.74 | NPC1 (0.41) | ALDH1A1ALOX15HSD17B10NPC1RAB9A | |
| SCHEMBL14652456 | 0.74 | NPC1 (0.41) | ALDH1A1HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL851358 | 0.73 | ALDH1A1 (0.69) | TGFBR1ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL29540343 | 0.73 | ALDH1A1 (0.69) | TGFBR1ALDH1A1HPGDALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064187-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | Clavius Pharmaceuticals, LLC. | 2022-03-03 | — | — | US | disclosed |
| US-11124509-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200239462-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS, LLC | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124509-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | TGFB1, TGFBR1, TGFB2 | TGFBR1 2/4885ALDH1A1 1635/4885HPGD 1177/4885 |
| US-20220064187-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | TGFB1, TGFBR1, TGFB2 | TGFBR1 2/4885ALDH1A1 2833/4885HPGD 3347/4885 |
| US-20200239462-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | TGFB1, TGFBR1, TGFB2 | TGFBR1 2/4885ALDH1A1 1635/4885HPGD 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.